After a delay Wave will finally see data for its Huntington's disease projects while Argenx's subcutaneous efgartigimod needs to keep the competition at bay.
After an overwhelmingly positive adcom, the outstanding question around Vascepa is just how big the product might become.
The period between a device company’s foundation and its acquisition has lengthened over the past few years, and currently stands at more than a decade.
Firmer evidence to support Assembly’s approach to vanquishing the hepatitis B virus will not emerge until next year, and rivals are not standing still in the meantime.
The pivotal portion of bardoxolone’s Cardinal study can’t match earlier data, but is still sufficient for filing.
Astrazeneca’s goal of bringing the second new lupus drug in over half a century to the market is a step closer, but all hangs on the FDA accepting mixed clinical data.
Nextcure’s Society for Immunotherapy of Cancer presentation gave investors little reason for cheer, but there's better news for Pieris, Celyad and Nektar.
A cardiac safety analysis should calm some concerns over Astrazeneca and Fibrogen’s new anaemia pill, though regulators’ views on the hugely complex programme remain…
Axsome hopes to find a niche with its migraine project, AXS-07, while Kala's latest phase III needs to win over the regulators.
Takeda’s pivotal trial has suggested that TAK-003 could work in both dengue-naïve and previously infected patients, making Sanofi’s Dengvaxia look irrelevant.
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
Supernus needs something to fill the gap left by its faltering epilepsy drug Trokendi XR, but SPN-810 isn’t it.
Fibrogen investors’ nerves jangle as another key cardiovascular safety readout approaches for the anaemia project.
Amarin’s Vascepa is widely expected to receive approval in a huge new patient population. So why has the company not been bought?
Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
Stryker’s scale-building efforts have been notable over the past few years, and at $4.7bn this is its largest-ever deal.
Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.
A multifaceted tie-up effectively gives Beigene a net $1.5bn fund-raising and several Amgen drugs to sell locally.